ProPharma Group, established in 2001 and based in the United States, operates within the Business Services sector, specifically focusing on management consulting. The company provides expertise in regulatory compliance and market access for the pharmaceutical and biotechnology industries, particularly concerning European Health Technology Assessment (HTA) regulations. Their published documents highlight the implications of the new European HTA Regulation (HTAR), which mandates the preparation of Joint Clinical Assessments (JCA) for companies seeking market authorization for medicinal products in Europe. ProPharma Group emphasizes its role in assisting clients with navigating these regulatory changes to ensure successful product launches. Additionally, the company explores the impact of decentralized manufacturing in cell and gene therapy, offering guidance on quality management systems and the use of artificial intelligence for improving trial master file classification. Through case studies and white papers, ProPharma Group demonstrates its commitment to enhancing quality and consistency in the life sciences sector, positioning itself as a knowledgeable partner for organizations aiming to meet complex regulatory requirements and optimize their product development processes.